Visegrad research meeting

Under the auspices of Czech Myeloma Group

Chairman: R. Hájek

Visegrad research meeting is project of Czech Myeloma Group. It provides a platform for international communication in the management of patients with monoclonal gammopathies. This year, in 2022, is meeting focused on the update of research and clinical activities of cell therapy. New topic as reflection of „covid era“ will be analysis related to covid vaccine in patients with haematological malignancies.

Wednesday 16. 3. 2022 (17:15–20:00 +)

17:15–17:20 Roman Hájek (Ostrava)
Welcome reception/dinner

PART I: Clinical topics – hematological malignancies, covid-19

17:20–17:35 Sebastian Giebel (Gliwice)
Allogeneic HCT for patients with MM. Gliwice experience.

17:35–17:50 Dominik Dytfeld (Poznan)
Update on studies of Polish Myeloma Consortium.

17:50–18:05 Artur Jurczyszyn (Krakow)
Monoclonal gammopathy of renal significance – Real world data on outcomes and prognostic factors.

18:05–18:20 Gabor Mikala (Budapest)
The role of mitochondrial exchange in therapy resistance of multiple myeloma.

18:15–18:30 Varga Gergely (Budapest)
sBCMA measurements as disease monitoring in nonsecretory multiple myeloma.

18:30–18:40 Ľubica Harvanová (Bratislava)
Difficult way to innovative drugs in Slovakia.

18:40–18:50 Ondřej Šušol (Ostrava)
Third dose of COVID-19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titres – a single centre experience.

Coffee break

PART II: Research topics – cell therapy projects and others

19:00–19:10 Tomasz Czerw (Gliwice)
Current status of CAR-T cell therapy (research) in Poland.

19:10–19:20 Jan Vydra (Praha)
Locally produced CART19 in UHKT – phase I study.

19:20–19:35 Monika Holubová (Plzeň)
Advantages of invariant NKT cells as a platform for cellular therapy in multiple myeloma.

19:35–19:45 Jan Frič (Praha)
Immunometabolism as a key to expansion and cytotoxicity of NK cells.

19:45–20:00 Piotr Cielichowski, Benjamin Motais (Ostrava)
Development of cell-based therapies in Ostrava – allogenic NK cells and CAR-T cells.

PART III: Discussion

20:00 +